Home LiteratureArticle Details
PMID: 19559599 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it.

Current opinion in structural biology ·Vol. 19 ·No. 4 ·2009-08-00 ·Pages 408-17

Lee JE, Saphire EO

Abstract

The ebolavirus (EBOV) envelope glycoprotein (GP) is solely responsible for viral attachment to, fusion with, and entry of new host cells, and consequently is a major target of vaccine design efforts. Recently determined crystal structures of key antibodies in complex with their EBOV epitopes have provided insights into the molecular architecture of GP and defined likely hotspots for viral neutralization. In this review, we discuss the structural basis for antibody-mediated neutralization of ebolavirus and its implications for novel therapeutic or vaccine strategies.

MeSH Terms
Animals Antibodies, Neutralizing/immunology Antibodies, Viral/immunology Ebolavirus/immunology,physiology Humans Mucins/chemistry Protein Structure, Tertiary Viral Envelope Proteins/chemistry,immunology,metabolism Virus Internalization
Chemicals
Antibodies, Neutralizing Antibodies, Viral Mucins Viral Envelope Proteins
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Lee Jeffrey E
Department of Immunology and Microbial Science, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.
Saphire Erica Ollmann
References (53)
53 references, click to expand
  1. Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections.
    J Infect Dis. 1999 Feb;179 Suppl 1:S218-23 PMID: 9988187
  2. Structure of the Ebola fusion peptide in a membrane-mimetic environment and the interaction with lipid rafts.
    J Biol Chem. 2007 Sep 14;282(37):27306-27314 PMID: 17545161
  3. The primed ebolavirus glycoprotein (19-kilodalton GP1,2): sequence and residues critical for host cell binding.
    J Virol. 2009 Apr;83(7):2883-91 PMID: 19144707
  4. Release of viral glycoproteins during Ebola virus infection.
    Virology. 1998 May 25;245(1):110-9 PMID: 9614872
  5. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels.
    J Virol. 2004 Oct;78(19):10370-7 PMID: 15367603
  6. Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme.
    Crit Rev Biochem Mol Biol. 2008 May-Jun;43(3):189-219 PMID: 18568847
  7. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995.
    J Infect Dis. 1999 Feb;179 Suppl 1:S177-87 PMID: 9988182
  8. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor.
    Nature. 2008 Jul 10;454(7201):177-82 PMID: 18615077
  9. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee.
    J Infect Dis. 1999 Feb;179 Suppl 1:S18-23 PMID: 9988160
  10. Structural basis of viral invasion: lessons from paramyxovirus F.
    Curr Opin Struct Biol. 2007 Aug;17(4):427-36 PMID: 17870467
  11. Preliminary report: isolation of Ebola virus from monkeys imported to USA.
    Lancet. 1990 Mar 3;335(8688):502-5 PMID: 1968529
  12. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans.
    J Virol. 2002 Jul;76(13):6841-4 PMID: 12050398
  13. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution.
    Nature. 1981 Jan 29;289(5796):366-73 PMID: 7464906
  14. Ebola virus can be effectively neutralized by antibody produced in natural human infection.
    J Virol. 1999 Jul;73(7):6024-30 PMID: 10364354
  15. Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995: determinants of survival.
    J Infect Dis. 1999 Feb;179 Suppl 1:S24-7 PMID: 9988161
  16. Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses.
    J Virol. 2003 Jan;77(2):1069-74 PMID: 12502822
  17. Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain.
    Mol Cell. 1998 Nov;2(5):605-16 PMID: 9844633
  18. Persistent infection with ebola virus under conditions of partial immunity.
    J Virol. 2004 Jan;78(2):958-67 PMID: 14694127
  19. Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry.
    J Virol. 2004 Mar;78(6):2943-7 PMID: 14990712
  20. Biosynthesis and role of filoviral glycoproteins.
    J Gen Virol. 2001 Dec;82(Pt 12):2839-2848 PMID: 11714958
  21. Ebola virus glycoprotein 1: identification of residues important for binding and postbinding events.
    J Virol. 2007 Jul;81(14):7702-9 PMID: 17475648
  22. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys.
    PLoS Pathog. 2007 Jan;3(1):e9 PMID: 17238286
  23. Isolation and partial characterisation of a new strain of Ebola virus.
    Lancet. 1995 May 20;345(8960):1271-4 PMID: 7746057
  24. Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor.
    J Biol Chem. 2006 Jun 9;281(23):15951-8 PMID: 16595665
  25. Recombinant human monoclonal antibodies to Ebola virus.
    J Infect Dis. 1999 Feb;179 Suppl 1:S235-9 PMID: 9988189
  26. Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein.
    J Virol. 2006 Apr;80(8):4174-8 PMID: 16571833
  27. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients.
    Nat Med. 1999 Apr;5(4):423-6 PMID: 10202932
  28. Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation.
    Nature. 2006 Jan 5;439(7072):38-44 PMID: 16397490
  29. Identification of two amino acid residues on Ebola virus glycoprotein 1 critical for cell entry.
    Virus Res. 2006 Nov;121(2):205-14 PMID: 16839637
  30. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs.
    PLoS Med. 2006 Jun;3(6):e177 PMID: 16683867
  31. Downregulation of beta1 integrins by Ebola virus glycoprotein: implication for virus entry.
    Virology. 2000 Dec 5;278(1):20-6 PMID: 11112476
  32. Complex of a protective antibody with its Ebola virus GP peptide epitope: unusual features of a V lambda x light chain.
    J Mol Biol. 2008 Jan 4;375(1):202-16 PMID: 18005986
  33. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection.
    Science. 2005 Jun 10;308(5728):1643-5 PMID: 15831716
  34. Production and characterization of monoclonal antibodies against different epitopes of Ebola virus antigens.
    J Virol Methods. 2007 Jul;143(1):29-37 PMID: 17368819
  35. Epitopes involved in antibody-mediated protection from Ebola virus.
    Science. 2000 Mar 3;287(5458):1664-6 PMID: 10698744
  36. Tyro3 family-mediated cell entry of Ebola and Marburg viruses.
    J Virol. 2006 Oct;80(20):10109-16 PMID: 17005688
  37. Human asymptomatic Ebola infection and strong inflammatory response.
    Lancet. 2000 Jun 24;355(9222):2210-5 PMID: 10881895
  38. Ectodomain shedding of the glycoprotein GP of Ebola virus.
    EMBO J. 2004 May 19;23(10):2175-84 PMID: 15103332
  39. Viral membrane fusion.
    Nat Struct Mol Biol. 2008 Jul;15(7):690-8 PMID: 18596815
  40. Folate receptor-alpha is a cofactor for cellular entry by Marburg and Ebola viruses.
    Cell. 2001 Jul 13;106(1):117-26 PMID: 11461707
  41. Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-A resolution.
    Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2662-7 PMID: 10077567
  42. An efficient platform for screening expression and crystallization of glycoproteins produced in human cells.
    Nat Protoc. 2009;4(4):592-604 PMID: 19373230
  43. Protective efficacy of neutralizing antibodies against Ebola virus infection.
    Vaccine. 2007 Jan 22;25(6):993-9 PMID: 17055127
  44. Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody.
    J Virol. 2002 Jun;76(12):6408-12 PMID: 12021376
  45. Proteolysis of the Ebola virus glycoproteins enhances virus binding and infectivity.
    J Virol. 2007 Dec;81(24):13378-84 PMID: 17928356
  46. Biochemical analysis of the secreted and virion glycoproteins of Ebola virus.
    J Virol. 1998 Aug;72(8):6442-7 PMID: 9658086
  47. Ebola virus-like particles protect from lethal Ebola virus infection.
    Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15889-94 PMID: 14673108
  48. Structure of the prefusion form of the vesicular stomatitis virus glycoprotein G.
    Science. 2007 Feb 9;315(5813):843-8 PMID: 17289996
  49. The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis.
    Arch Virol Suppl. 1999;15:159-69 PMID: 10470276
  50. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing.
    Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3602-7 PMID: 8622982
  51. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution.
    Nature. 1995 May 25;375(6529):291-8 PMID: 7753193
  52. Crystal structure of glycoprotein B from herpes simplex virus 1.
    Science. 2006 Jul 14;313(5784):217-20 PMID: 16840698
  53. Comprehensive analysis of ebola virus GP1 in viral entry.
    J Virol. 2005 Apr;79(8):4793-805 PMID: 15795265
Article Info
Journal
Current opinion in structural biology
Abbr.
Curr Opin Struct Biol
ISSN
1879-033X
DOI
10.1016/j.sbi.2009.05.004
Published
2009-08-00
Epub
2009-00-24
Pages
408-17
Language
English
Region
England
NLM ID
9107784
PMCID
PMC2759674
Subset
IM
Grants
NIAID NIH HHS · R21 AI053423-01 · United States
NIAID NIH HHS · R01 AI067927-01A1 · United States
NIAID NIH HHS · R01 AI067927-02 · United States
NIAID NIH HHS · AI067927 · United States
NIAID NIH HHS · R01 AI067927-03 · United States
NIAID NIH HHS · AI053423 · United States
NIAID NIH HHS · R21 AI053423-02 · United States
NIAID NIH HHS · R01 AI067927 · United States
External Links
PubMed source DOI: 10.1016/j.sbi.2009.05.004 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2